TESARO Initiates Phase 3 Trial of Niraparib for Treatment of Patients with Ovarian Cancer
First Patients Enrolled in the NOVA Study
WALTHAM, Mass., July 23, 2013 (GLOBE NEWSWIRE) — TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that it has initiated patient enrollment in a Phase 3 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP), for the treatment of ovarian cancer. This trial, referred to as NOVA, will evaluate a single daily 300 milligram dose of niraparib in 360 patients with high grade serous, platinum sensitive, relapsed ovarian cancer compared to placebo.
© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.